With our acquisition of Megan Health in 2000, AVANT gained access to technologies for developing vaccines against Campylobacter and enterotoxigenic E. coli (ETEC). When combined with our existing Shigella vaccine program, AVANT now has three travelers' vaccine programs in pre-clinical development - all addressing important causes of serious diarrheal diseases worldwide. AVANT is pursuing a strategy to develop a combination travelers' vaccine from these programs. Market research indicates that a two-vaccine combination product containing ETEC and either a Shigella or Campylobacter vaccine addressed to the travelers' market could achieve annual peak sales of over $600 million.